Last updated: April 26, 2026
Who supplies ethacrynate sodium (API and finished dosage forms)?
Ethacrynate sodium is a legacy diuretic API that is marketed in small, older product portfolios and is sourced through established generic/API supply chains. In practice, supply comes from two channels: (1) API manufacturers supplying ethacrynate sodium as a chemical raw material, and (2) finished-dose manufacturers selling branded or generic ethacrynate sodium products to wholesalers in regulated markets.
Because supplier identity and availability change frequently and product dossiers vary by jurisdiction, a complete, correct supplier list cannot be produced from the information provided in the prompt alone.
What suppliers are actually verifiable from the provided inputs?
No supplier names, product registrations, site licenses, DMFs/EDMFs, or market authorizations are included in the prompt. Without at least one of the following, a complete and accurate “supplier for ETHACRYNATE SODIUM” response cannot be constructed:
- specific dosage form (tablet, injection, etc.) and strength
- specific country/market (US, EU, UK, etc.)
- specific label/marketing authorization holder
- any referenced catalogs, registration databases, or DMF/EDMF holders
What sourcing data can be used to benchmark supplier suitability (without naming suppliers)?
Even without identifying specific companies, procurement teams typically validate against these hard filters for ethacrynate sodium:
Regulatory and documentation requirements
- API quality system alignment with cGMP for API manufacture
- DMF/EDMF status (US DMF or EU EDMF) for API grade supplied to US/EU formulators
- CoA and specification controls per pharmacopeial/USP or internal monograph targets
Quality control checkpoints
- Assay and impurities aligned to API specification
- Solubility and physical form consistency (critical for older actives with narrow historical formulation margins)
- Sterility/non-sterility controls if supplied for injection manufacturing (finished forms only)
Commercial supply chain checkpoints
- Batch release lead times
- Consistent packaging format (drum vs. bottle, nitrogen blanketing where applicable)
- Temperature and humidity handling requirements for transit
Key Takeaways
- ETHACRYNATE SODIUM sourcing is handled through API and finished-dose supply chains, but the prompt provides no verifiable supplier identifiers.
- A supplier list that is complete and accurate requires market-specific registrations or company-level documentation, none of which are present in the provided information.
- Procurement teams should benchmark suppliers using cGMP alignment, DMF/EDMF availability, CoA/spec controls, and release lead-time reliability.
FAQs
-
Is ethacrynate sodium supplied mainly as an API or as finished medication?
Both exist in the market, but legacy actives often have fewer manufacturers and narrower finished-dose coverage depending on geography.
-
What documentation matters most when qualifying an ethacrynate sodium API supplier?
DMF/EDMF status (where applicable), CoA content, and evidence that the API manufacture and controls align with regulatory expectations.
-
Do ethacrynate sodium suppliers differ by dosage form (oral vs injection)?
Yes. Injection manufacturing often imposes additional controls on grade suitability and constraints on impurities and form.
-
How should companies handle supply risk for legacy APIs like ethacrynate sodium?
Validate multiple qualified sources, lock specs early, and assess batch-to-batch consistency based on CoA and impurity profiles.
-
What determines whether an API supplier can serve US vs EU markets?
Whether the supplier supports the required regulatory pathways for those markets (for example, DMF/EDMF readiness) and can meet relevant monograph and registration expectations.
References
[1] No sources were provided in the prompt.
